Emergent Makes Plans For Narcan Nasal Spray Competition
Awaiting Verdict In Litigation With Teva Over Patents Protecting Nasal Naloxone
Adapt Pharma parent company Emergent BioSolutions has revealed plans to defend its Narcan nasal naloxone brand against potential generic competition in the US, including through an authorized generic deal with a major generics firm, as it awaits the outcome of litigation with Teva.
You may also be interested in...
Shortly after agreeing to provide the state of Texas with its generic version of Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray, Teva has secured victory in patent-invalidity proceedings.
Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.